Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke
A prospective, single-center study would be carried out in the Neurology Department of the University Hospital "Dr. José Eleuterio González" in order to analyze the effect of cerebrolysin on the blood-brain-barrier in patients with ischemic stroke with personal history of type-2 diabetes
Study InterventionsCerebrolysin, Brain-MRI with contrast after 10-14 days of cerebrolysinPrimary EndpointsBlood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral arteryStudy Period2022-11-17 → 2024-12 Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study
The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.
Study InterventionsCerebrolysin treatment, Standard treatment (including neurorehabilitation) of acute ischemic strokePrimary Endpoints90-day Action Research Arm Test (ARAT) Score changeStudy Period2025-06-13 → 2027-10-15 Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.
Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's very important to choose the right way of the management of the patient and an appropriate drugs.
There is a large number of the so-called neuroprotective drugs, which were effective in laboratory, but didn't show positive results in clinical studies with using traditional clinical scales scores as a primary
Study Interventionsciticoline, L-Alpha glycerylphosphorylcholine, cerebrolysinPrimary EndpointsMEP(motor evoked potential) parameter: motor threshold; MEP(motor evoked potential) parameter: latencyStudy Period2011-01 → 2011-11 Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy
Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of $11.5 billion or $921,000 average cost per person. Associated disabilities as mental retardation, delayed speech development
Study InterventionsCerebrolysin (Nerve growth factor)Primary EndpointsneurodevelopmentStudy Period2014-04 → 2016-04 Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage
This is a randomized, placebo-controlled, single-center clinical trial investigating the effectiveness of administrating intravenous Cerebrolysin™ (EVER NEURO Pharma, Austria), a preparation of low-molecular weight neurotrophic peptides and free amino acids, in improving the functional outcome of patients suffering from aneurysmal subarachnoid haemorrhage ( SAH).
Cerebrolysin™ is a porcine-derive
Study InterventionsIntravenous Cerebrolysin, Normal SalinePrimary EndpointsGlobal functional performanceStudy Period2013-12-01 → 2019-01-01 Cerebrolysin in Critically Ill Patients With Delirium
Delirium is a severe problem in critically ill patients, and it is associated with increased morbidity, mortality, and extended stay in hospital. The pathophysiology of delirium is multifactorial and still poorly recognized. Several authors proposed different pathomechanisms of delirium. The most likely of these are a metabolic response to cerebral hypoxia/hyperoxia, oxidative stress with excessiv
Study InterventionsCerebrolysin, Saline Solution - IVPrimary EndpointsCAM-ICU test; ICDSC testStudy Period2024-01-01 → 2025-12-31 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to donepezil in patients with mild to moderate dementia of Alzheimer's Type (DAT). In addition, a traditional approach will be taken based on the evaluation of the separate risk and benefit domains in comparison with donepezil.
Global risk-benefit as compared to donepezil will be analyzed by determining
Study InterventionsCerebrolysin, DonepezilPrimary EndpointsChange from Baseline in ADAS-cog. and CIBIC+ score distribution Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study
" This study aims to measure changes in language ability after adding cerebrolysin to standard treatment for non-fluent aphasia patients with post-stroke language impairment. The patients are divided into two groups: the experimental group, which receives a combination of standard treatment (speech therapy) and cerebrolysin, and the control group, which only receives standard treatment (speech the
Study InterventionsCerebrolyisin, PlaceboPrimary EndpointsParadise Korean Western Aphasia Battery (PK-WAB)Study Period2025-03-12 → 2027-12-31 Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
The goal of this interventional study is to Measure the potential benefits of combined administration of cerebrolysin and amantadine sulfate as an add-on therapy to the standard management of patients admitted to the ICU with traumatic brain injury.
Study InterventionsCerebrolysin, amantadine sulfatePrimary EndpointsThe Glasgow Coma Scale (GCS); Disability rating-scale for severe head trauma (DRS)Study Period2023-09-01 → 2025-08-01 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm
The aim of the present clinical phase IV study is to estimate the influence of Cerebrolysin in combination with standard therapy on the dynamics of recovery of the paretic upper limb in patients with acute ischemic stroke.
Each patient participates in the study for 176-190 days (approximately 6 months). The estimated duration of the study is 2 years.
Study InterventionsCerebrolysin infusion, Placebo infusionPrimary EndpointsOverall dynamics of the hand function assessed by the Frenchay Arm TestStudy Period2015-02 → 2017-02